[摘要] 目的 研究糖尿病與C-肽釋放試驗的相關性。方法 對200例糖尿病與160例正常人進行C-肽釋放試驗,操作方法與口服葡萄糖耐量試驗(OGTT)一樣,分別測定空腹水平、餐后30、60、120、180min的C-肽水平;然后進行比較分析。結果 I型糖尿病患者各時相C-肽濃度值均低于正常人(P<0.01);II型糖尿病患者各時相C-肽濃度值均低于正常人(P<0.01);I型糖尿病患者各時相C-肽濃度值均低于II型糖尿病患者(P<0.01)。結論 C-肽釋放試驗可以對糖尿病進行分型,預測糖尿病患者病變的程度;控制血糖水平、穩定C-肽水平,能減少糖尿病患者多器官受損的發生。
[關鍵詞] C-肽; 糖尿??; C-肽釋放試驗; 口服葡萄糖耐量試驗
[中圖分類號] R587.1 [文獻標識碼] A [文章編號] 1673-9701(2009)13-106-02
Relativity Analysis of Diabetes and C-peptide Release Test
GUO Zhaolin
Department of Clinical Laboratory,Chaoyang Dafeng Hospital,Guangdong 515100
[Abstract] ObjectiveTo research relativity of diabetes and C-peptide release test. Methods200 diabetes patients and 160 normal people were carried out C-peptide release test. Its operation was the same as oral glucose tolerance test(OGTT). C-peptide level of limosis,postprandial 30min, postprandial 60min,postprandial 120min,postprandial 180min were determined respectively. And then compared and analysed. ResultsC-peptide concentration values of type 1 diabetes patients and type 2 diabetes patients were all lower than normal people(P<0.01). And C-peptide concentration values of type 1 dabetes patients was all lower than type 2 diabetes patients(P<0.01). Conclusion C-peptide release test can dispart diabetes type. It can prognosticate pathological changes deree of diabetes patients. Controlling blood glucose and levelling off C-peptide level can decrease the incidence of multi-organ injury.
[Key Words]C-peptide; Diabetes; C-peptide release test; OGTT
C-肽是含31個氨基酸的多肽,它和胰島素的A、B鏈組成胰島素原,是A、B鏈的連接肽(connecting peptide),在胰島素原分子的折疊、二硫鍵的正確配對中起重要作用。C-肽由胰島素原裂解產生,一分子胰島素原合成一分子C-肽與一分子的A、B鏈,后二者合成胰島素[1]。近年來,2型糖尿病患者逐漸增多,胰島β細胞功能受損和胰島素抵抗是2型糖尿病病理生理基礎,測定血漿胰島素和C-肽可反映胰島β細胞功能。眾所周知,胰島β細胞胰島素分泌的缺陷是糖尿病的重要病理生理基礎。1型糖尿病患者胰島素絕對分泌不足,其C-肽水平明顯低于正常。2型糖尿病早期為胰島素抵抗,臨床上以高胰島素血癥為主,C-肽也有所上升,而后期胰島β細胞功能衰竭,胰島素與C-肽均下降。因此,胰島素被用于判斷β細胞功能。由于C-肽與胰島素呈等分子分泌,較胰島素的半衰期長,C-肽與胰島素比值在血中恒定(5∶1 ~ 10∶1),二者的峰值曲線相同,因而C-肽釋放試驗的測定可以更好地反映β細胞生成和分泌胰島素的能力。……